Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide
and has a poor prognosis. Current treatments for advanced NSCLC included traditional …

Recent progress in cancer biology has led to the discovery of increasing number of
oncogene alterations that have dramatically changed the paradigm of lung cancer treatment …

MET or hepatocyte growth factor (HGF) receptor pathway signaling mediates wound healing
and hepatic regeneration, with pivotal roles in embryonic, neuronal, and muscle …

The hepatocyte growth factor receptor (MET) is a potential therapeutic target in a number of
cancers, including NSCLC. In NSCLC, MET pathway activation is thought to occur through a …

Recently, a better understanding of the specific mechanisms of oncogene addiction has led
to the development of antitumor strategies aimed at blocking these abnormalities in different …

Lung cancer is a heterogeneous group of disorders that is now being subdivided into
molecular subtypes with dedicated targeted therapies. The MET receptor tyrosine kinase …

Over the years, there has been a continuous increase in clinically relevant driver mutations
in patients with non–small cell lung cancer (NSCLC). Among these, dysregulated activation …

A better understanding of the pathophysiology and evolution of non‐small cell lung cancer
(NSCLC) has identified a number of molecular targets and spurred development of novel …

MET is a versatile receptor tyrosine kinase within the human kinome which is activated by its
specific natural ligand hepatocyte growth factor (HGF). MET signaling plays an important …

The receptor tyrosine kinase MET has been studied of a large variety of human cancers,
including lung and mesothelioma. The MET receptor and its ligand HGF (hepatocyte growth …